FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
30 Jan 2023
EORTC, CTI, and IRROG collaboration opens new opportunities in Ireland
12 Dec 2022
Results of two EORTC studies have been published in NEJM and the Lancet Oncology
21 Sep 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
17 Mar 2022
KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
10 Jan 2022
New results from immunotherapy trials from the EORTC gynaecological and lung cancer groups presented at ESMO 2021
20 Sep 2021
PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
20 Jan 2021
New Data Gives Hope to Small Cell Lung Cancer Patients
18 Sep 2020
